ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BCG Vaccine

Also written as “BCG”, “BCG for Therapeutic Use” and “Bacillus Calmette-Guerin”.

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Tuberculosis · Alzheimer Disease · Melanoma, led by 10 companies.

Drug pageBCG Vaccine: every studyMany companies study it; this page follows only the 16 they lead. All 103 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Mar 14, 201616 company-led studies, 8 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Zhifei Biological Productsits history only41 open or runningphase 3since Mar 14, 2016Mar 5, 2015Apr 30, 2028phase 3 · NCT06747455
ImmunityBio32 open or runningphase 3since Apr 20, 2026May 13, 2014Nov 2026phase 2 · NCT06829823
Chengdu CoenBiotechits history only21 open or runningphase 3since Jan 28, 2024Jan 28, 2024none ahead
AstraZenecaits history only11 open or runningphase 3since Jul 5, 2023Jul 5, 2023none ahead
Heat Biologicsits history only10 open or runningphase 2since Dec 5, 2013Dec 5, 2013none ahead
Laboratorio Pablo Cassará S.R.L.its history only10 open or runningphase 3since Nov 14, 2012Nov 14, 2012none ahead
Merckits history only11 open or runningphase 2since Feb 4, 2025Feb 4, 2025Sep 3, 2031phase 2 · NCT06833073
Mindful Diagnostics and Therapeuticsits history only10 open or runningphase 2since Jun 24, 2020Jun 24, 2020none ahead
Pfizerits history only11 open or runningphase 3since Nov 13, 2019Nov 13, 2019none ahead
Verity Pharmaceuticalsits history only11 open or runningphase 3since Jul 28, 2021Jul 28, 2021Feb 2029phase 3 · NCT05037279

Also a collaborator on its studies: Moderna, Parexel and Proswell Medical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ImmunityBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2014First study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsFirst studyNCT02138734 · 369 enrolled · United States, India, South Africa
  2. Feb 5, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06829823 · 20 planned
  3. Apr 20, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsPhase 3 reachedNCT07551544

Ahead

  1. Nov 2026Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06829823

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities”NCIt, by rule

Studies

All 3 ImmunityBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07551544Non-Muscle Invasive Bladder Neoplasms3WithdrawnMay 20320
NCT06829823Non-Muscle Invasive Bladder Neoplasms2Not yet recruitingNov 202620
NCT02138734Non-Muscle Invasive Bladder Neoplasms · United States, India, South Africa2Active, not recruitingSep 30, 2026369

How it is read

Names in the registry

  • “BCG”, 4 entries
  • “BCG for Therapeutic Use”, 4 entries
  • “Bacillus Calmette-Guerin”, 1 entry
  • “BCG (50 mg) plus ANKTIVA (400 µg)”, 1 entry
  • “BCG (50 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.